000284096 001__ 284096
000284096 005__ 20260126095215.0
000284096 0247_ $$2doi$$a10.1016/j.pbb.2014.04.008
000284096 0247_ $$2ISSN$$a0091-3057
000284096 0247_ $$2ISSN$$a1873-5177
000284096 037__ $$aDZNE-2026-00104
000284096 041__ $$aEnglish
000284096 082__ $$a540
000284096 1001_ $$aGodin, Adriana M.$$b0
000284096 245__ $$aActivities of 2-phthalimidethanol and 2-phthalimidethyl nitrate, phthalimide analogs devoid of the glutarimide moiety, in experimental models of inflammatory pain and edema
000284096 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2014
000284096 3367_ $$2DRIVER$$aarticle
000284096 3367_ $$2DataCite$$aOutput Types/Journal article
000284096 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769417421_1864
000284096 3367_ $$2BibTeX$$aARTICLE
000284096 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284096 3367_ $$00$$2EndNote$$aJournal Article
000284096 520__ $$aThe reintroduction of thalidomide in the pharmacotherapy greatly stimulated the interest in the synthesis and pharmacological evaluation of phthalimide analogs with new and improved activities and also greater safety. In the present study, we evaluated the activities of two phthalimide analogs devoid of the glutarimide ring, namely 2-phthalimidethanol (PTD-OH) and 2-phthalimidethyl nitrate (PTD-NO), in experimental models of inflammatory pain and edema in male C57BL/6J mice. Intraplantar (i.pl.) injection of carrageenan (300 μg) induced mechanical allodynia and this response was inhibited by previous per os (p.o.) administration of PTD-OH and PTD-NO (750 mg/kg) and also by thalidomide (500 or 750 mg/kg). The edema induced by carrageenan was also inhibited by previous p.o. administration of PTD-OH (500 and 750 mg/kg) and PTD-NO (125, 250, 500 or 750 mg/kg), but not by thalidomide. Carrageenan increased tumor necrosis factor (TNF)-α and CXCL1 concentrations and also the number of neutrophils in the paw tissue. Previous p.o. administration of PTD-NO (500 mg/kg) reduced all the parameters, while PTD-OH (500 mg/kg) reduced only the accumulation of neutrophils. Thalidomide, on the other hand, was devoid of effect on these biochemical parameters. Plasma concentrations of nitrite were increased after p.o. administration of the phthalimide analog coupled to a NO donor, PTD-NO (500 mg/kg), but not after administration of PTD-OH or thalidomide. In conclusion, our results show that small molecules, structurally much simpler than thalidomide or many of its analogs under investigation, exhibit similar activities in experimental models of pain and inflammation. Finally, as there is evidence that the glutarimide moiety contributes to the teratogenic effect of many thalidomide analogs, our results indicate that phthalimide analogs devoid of this functional group could represent a new class of analgesic and anti-inflammatory candidates with potential greater safety.
000284096 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000284096 588__ $$aDataset connected to DataCite
000284096 650_7 $$2Other$$a2-Phthalimidethanol
000284096 650_7 $$2Other$$a2-Phthalimidethyl nitrate
000284096 650_7 $$2Other$$aInflammation
000284096 650_7 $$2Other$$aPain
000284096 650_7 $$2Other$$aPhthalimide analogs
000284096 650_7 $$2Other$$aThalidomide
000284096 650_7 $$2NLM Chemicals$$aKetoglutaric Acids
000284096 650_7 $$2NLM Chemicals$$aPhthalimides
000284096 650_7 $$01J6PQ7YI80$$2NLM Chemicals$$aphthalimide
000284096 650_7 $$025335-74-4$$2NLM Chemicals$$aglutaramic acid
000284096 650_7 $$09000-07-1$$2NLM Chemicals$$aCarrageenan
000284096 650_2 $$2MeSH$$aAnimals
000284096 650_2 $$2MeSH$$aCarrageenan: toxicity
000284096 650_2 $$2MeSH$$aDisease Models, Animal
000284096 650_2 $$2MeSH$$aEdema: chemically induced
000284096 650_2 $$2MeSH$$aEdema: drug therapy
000284096 650_2 $$2MeSH$$aEdema: metabolism
000284096 650_2 $$2MeSH$$aInflammation: drug therapy
000284096 650_2 $$2MeSH$$aInflammation: metabolism
000284096 650_2 $$2MeSH$$aKetoglutaric Acids: chemistry
000284096 650_2 $$2MeSH$$aMale
000284096 650_2 $$2MeSH$$aMice
000284096 650_2 $$2MeSH$$aMice, Inbred C57BL
000284096 650_2 $$2MeSH$$aPain: drug therapy
000284096 650_2 $$2MeSH$$aPain: metabolism
000284096 650_2 $$2MeSH$$aPain Measurement: drug effects
000284096 650_2 $$2MeSH$$aPain Measurement: methods
000284096 650_2 $$2MeSH$$aPhthalimides: chemistry
000284096 650_2 $$2MeSH$$aPhthalimides: therapeutic use
000284096 7001_ $$aAraújo, Débora P.$$b1
000284096 7001_ $$aMenezes, Raquel R.$$b2
000284096 7001_ $$aBrito, Ana Mercy S.$$b3
000284096 7001_ $$aMelo, Ivo S. F.$$b4
000284096 7001_ $$aCoura, Giovanna M. E.$$b5
000284096 7001_ $$aSoares, Darly G.$$b6
000284096 7001_ $$aBastos, Leandro F. S.$$b7
000284096 7001_ $$aAmaral, Flávio A.$$b8
000284096 7001_ $$0P:(DE-2719)9001782$$aSecchim Ribeiro, Lucas$$b9$$udzne
000284096 7001_ $$aBoff, Daiane$$b10
000284096 7001_ $$aSantos, Julliana R. A.$$b11
000284096 7001_ $$aSantos, Daniel A.$$b12
000284096 7001_ $$aTeixeira, Mauro M.$$b13
000284096 7001_ $$ade Fátima, Ângelo$$b14
000284096 7001_ $$aMachado, Renes R.$$b15
000284096 7001_ $$aCoelho, Márcio M.$$b16
000284096 773__ $$0PERI:(DE-600)2008734-2$$a10.1016/j.pbb.2014.04.008$$gVol. 122, p. 291 - 298$$p291 - 298$$tPharmacology, biochemistry and behavior$$v122$$x0091-3057$$y2014
000284096 8564_ $$uhttps://pub.dzne.de/record/284096/files/DZNE-2026-00104_Restricted.pdf
000284096 8564_ $$uhttps://pub.dzne.de/record/284096/files/DZNE-2026-00104_Restricted.pdf?subformat=pdfa$$xpdfa
000284096 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001782$$aExternal Institute$$b9$$kExtern
000284096 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000284096 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000284096 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHARMACOL BIOCHEM BE : 2022$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000284096 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000284096 920__ $$lyes
000284096 980__ $$ajournal
000284096 980__ $$aI:(DE-2719)1040260
000284096 9801_ $$aEXTERN4VITA